10-Q: Brainstorm Cell Therapeutics Reports Q1 2025 Results, Navigates Nasdaq Compliance

Brainstorm Cell Therapeutics announces its Q1 2025 financial results, highlighting ongoing efforts to regain Nasdaq compliance and advance its NurOwn program.

Summary

• Brainstorm Cell Therapeutics reported a net loss of $2.864 million for the quarter ended March 31, 2025, compared to a net loss of $3.401 million for the same period in 2024.
• Research and development expenses increased to $1.304 million, up from $961,000 in the prior year's quarter.
• General and administrative expenses also rose to $1.785 million from $1.513 million.
• The company is working to regain compliance with Nasdaq listing requirements, with an extension granted until June 30, 2025, contingent on meeting certain conditions.
• Brainstorm entered into an inducement offer to encourage the exercise of existing warrants, potentially raising $1.64 million.
• The company submitted an IND amendment to the FDA for NurOwn in ALS.
• As of May 11, 2025, the number of shares outstanding of the registrant's Common Stock was 7,938,876.
• The company has an accumulated deficit of approximately $229,000 as of March 31, 2025.
• The company's cash balance is $1,644 as of March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in some areas, such as submitting an IND amendment and pursuing capital raising, it faces significant challenges, including financial losses, Nasdaq compliance issues, and a material weakness in internal controls.

Positives

• The company has been granted an extension by Nasdaq to regain compliance with listing requirements.
• Brainstorm has submitted an IND amendment to the FDA for NurOwn in ALS, indicating continued progress in its clinical development program.
• The company is actively pursuing capital raising activities to meet Nasdaq requirements.
• The company has $1,644 in cash and cash equivalents as of March 31, 2025.

Negatives

• Brainstorm reported a net loss of $2.864 million for Q1 2025.
• The company is not currently in compliance with Nasdaq listing requirements.
• There is a material weakness in the company's internal control over financial reporting related to short-term loans.
• The company has an accumulated deficit of approximately $229,000 as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The company faces ongoing legal proceedings, including securities class action and derivative lawsuits.
• Raising additional capital may not be possible on favorable terms or at all.
• The company has a material weakness in internal control over financial reporting.

Future Outlook

The company plans to continue its clinical development of NurOwn, particularly in ALS, and is exploring options for other indications like PMS and AD. Additional funding will be required to support these activities and potential commercialization efforts.

Industry Context

Brainstorm is operating in the competitive field of cell therapies for neurodegenerative diseases, where there is a high unmet need. The company's focus on ALS and PMS aligns with areas of significant patient need and limited treatment options.

Comparison to Industry Standards

• It is difficult to compare Brainstorm's results directly to industry standards due to the unique nature of its autologous cell therapy approach.
• Companies like Amylyx Pharmaceuticals with their drug Relyvrio for ALS have achieved regulatory approval, setting a benchmark for demonstrating efficacy in this challenging disease area.
• Other companies such as Biogen and Ionis Pharmaceuticals are also developing treatments for ALS, creating a competitive landscape.
• Brainstorm's approach differs from gene therapy companies like Novartis and Sarepta Therapeutics, which focus on genetic modifications to treat diseases.
• The company's financial position is weaker than larger pharmaceutical companies, requiring it to carefully manage its resources and seek additional funding.

Legal Proceedings

• The company is involved in a securities class action lawsuit and multiple derivative lawsuits related to NurOwn and communications with the FDA.
• 3D Communications, LLC filed a lawsuit against the Company in the U.S. District Court for the District of Delaware, captioned 3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc., Case No. 1:24-cv-01286.

Related Party Transactions

• On November 4, 2024, the Company entered into a loan agreement with a related party for a principal amount of $120,000.

Stakeholder Impact

• Shareholders face the risk of stock dilution from potential capital raises and the risk of delisting from Nasdaq.
• Employees' job security is tied to the company's ability to secure funding and advance its clinical programs.
• Patients with ALS and other neurodegenerative diseases are awaiting the potential approval of NurOwn as a treatment option.
• The company's suppliers and creditors are dependent on its financial stability.

Next Steps

• Continue efforts to regain compliance with Nasdaq listing requirements.
• Advance the clinical development of NurOwn, particularly in ALS.
• Explore options for other indications like PMS and AD.
• Secure additional funding to support operations and clinical programs.

Key Dates

Keywords

NurOwn, ALS, Nasdaq, Clinical Trial, FDA, BLA, Brainstorm Cell Therapeutics, Financial Results, Stem Cell Therapy, Biotechnology